Curious phrasing in the latest PR - "The Compa
Post# of 148187
(Total Views: 486)
Posted On: 03/31/2021 11:37:51 PM
Curious phrasing in the latest PR -
"The Company believes this data provides an opportunity to expound upon the advice and expertise of our Key Opinion Leaders to optimize the dosing of leronlimab for further clinical benefit."
Who are these "Key Opinion Leaders" and who are they going to "expound" to, the FDA? Are they our Scientific Advisory Board or what? When?
Actually, the way it is written is the data gives the company the opportunity to expound to someone(?) about the advice and expertise of our Key Opinion Leaders concerning the optimization of leronlimab dosing for future clinical benefit.
What? To shareholders or to someone that holds our fate in their hands? Or the public at large?
"The Company believes this data provides an opportunity to expound upon the advice and expertise of our Key Opinion Leaders to optimize the dosing of leronlimab for further clinical benefit."
Who are these "Key Opinion Leaders" and who are they going to "expound" to, the FDA? Are they our Scientific Advisory Board or what? When?
Actually, the way it is written is the data gives the company the opportunity to expound to someone(?) about the advice and expertise of our Key Opinion Leaders concerning the optimization of leronlimab dosing for future clinical benefit.
What? To shareholders or to someone that holds our fate in their hands? Or the public at large?
(1)
(0)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼